Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).

Marc Thill Pauline Wimberger Andrea GrafePeter KlareKerstin Luedtke-HeckenkampDietmar ReichertMatthias ZaissKatja Ziegler-LöhrTanja EcklAndreas Schneeweiß

Published in: Breast cancer research and treatment (2022)

Based on the outcomes from NIS HELENA, results of dual blockade with P+T in patients relapsing after (neo)adjuvant T as reported from the CLEOPATRA study (NCT01777958) can be transferred to routine clinical practice. No new safety signals were detected.

Keyphrases

metastatic breast cancer
clinical practice
multiple sclerosis
end stage renal disease
epidermal growth factor receptor
newly diagnosed
ejection fraction
rheumatoid arthritis
disease activity
peritoneal dialysis
prognostic factors
systemic lupus erythematosus
patient reported outcomes
combination therapy